Loading quotes...
Forecast
The analysts' average price target is 2,70€ (−7,22%). The median is 2,49€ (−14,43%).
| Buy |
3 |
| Hold |
9 |
| Sell |
3 |
News Go to news feed
Cronos Group hits 52-week high after strong Q2 results
The Cronos Group share rose to a 52-week high of $3.44, with a market capitalization of $1.25 billion and year-to-date performance of 25.86%. InvestingPro points to an overvaluation versus fair value. Cronos beat expectations in Q2 2026 with revenue of $53 million (expectation $44.73 million), adjusted EPS of $0.09 (expectation $0.01), gross profit of $28.5 million and adjusted EBITDA of $13.1 million; cash and investments amounted to $827 million, and $60 million in share buybacks were reported. » More on de.investing.com
Cronos shares rise after Q2 results significantly beat expectations
Cronos reported Q2 EPS of $0.09 (consensus $0.01) and revenue of $53.0 million versus expected $44.73 million. The company reported record net revenue, gross profit and adjusted EBITDA, organic revenue growth of 51% and record sales in Israel, Canada and Germany. Cronos repurchased a total of 12.3 million shares in H1 2026. The strong company-specific metrics pushed the stock sharply higher in pre-market trading and brought it closer to its 52-week high. » More on de.investing.com
Cronos Group names ATB Capital Markets as broker for share buyback program
Cronos Group has appointed ATB Capital Markets Corp. (ATB Cormark) as broker for share repurchases on the Toronto Stock Exchange and other Canadian trading systems, replacing Virtu Canada Corp. The company gave no details on the reasons, size or timing of the buyback program. Cronos has most recently pursued an aggressive buyback strategy, which coincided with a 49% share price increase last year; market capitalization is around USD 1.04 billion. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 61,86M | 117,93% |
| Gross profit | 24,93M | 102,58% |
| Net profit | 28,11M | 183,44% |
| EBITDA | 31,63M | 10.629,72% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 1,14Md€ |
Number of shares | 373,66M |
52-week high/low | 3,07€ - 1,96€ |
| Dividends | No |
Beta | 1,24 |
P/E ratio | 18,99 |
PEG ratio | 0,00 |
P/B ratio | 1,25 |
P/S ratio | 7,44 |
Company profile
Die Cronos Group Inc. ist als Cannabinoid-Unternehmen tätig. Es produziert, vermarktet und vertreibt aus Hanf gewonnene Nahrungsergänzungsmittel und kosmetische Produkte über E-Commerce-, Einzelhandels- und Gaststättenpartnerkanäle unter den Marken Lord Jones und Happy Dance in den Vereinigten Staaten. Das Unternehmen befasst sich auch mit dem Anbau, der Herstellung und der Vermarktung von Cannabis und Cannabisprodukten für den medizinischen Markt und den Markt für den Gebrauch durch Erwachsene. Es verkauft Cannabis und Cannabisprodukte, darunter getrocknetes Cannabis, Pre-Rolls, Esswaren, Konzentrate und Cannabisextrakte über Großhandels- und Direktvertriebskanäle unter seiner Wellness-Plattform PEACE NATURALS und ist unter der Marke Spinach für den Gebrauch durch Erwachsene tätig. Das Unternehmen exportiert auch getrocknetes Cannabis und Cannabisöle nach Deutschland, Israel und Australien. Die Cronos Group Inc. wurde im Jahr 2012 gegründet und hat ihren Sitz in Toronto, Kanada.
| Name | Cronos |
| CEO | Michael Ryan Gorenstein |
| Headquarters | Stayner,
on Canada |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 02/27/2018 |
| Employees | 610 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CRON |
Toronto Stock Exchange | CRON.TO |
Frankfurt | 7CI.F |
Düsseldorf | 7CI.DU |
München | 7CI.MU |
Discover assets
Shareholders of Cronos also invest in the following assets

